Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Background: Taxane plays a key role in the treatment of breast cancer and taxane-induced
peripheral neuropathy (TIPN) is a dose-limiting adverse effect leading to treatment
discontinuation. Ganglioside-monosialic acid (GM1) functions as a neuroprotective factor.
However, the effects of GM1 on TIPN in breast cancer patients remains unknown.
Purpose: This randomized phase III trial is designed to evaluate the potential effects of GM1
for preventing TIPN in breast cancer patients.